Articles tagged with Melanoma
Researchers at H. Lee Moffitt Cancer Center & Research Institute have discovered a way to enhance immunotherapy for NRAS-mutant melanoma. Blocking nitrosylation triggers immunogenic cell death, attracting immune cells to destroy cancer cells and limiting tumor growth.
Researchers used AI-driven methods to analyze thousands of digital images of melanoma tumor tissue, identifying key immune cell structures that boost immunotherapy effects. The presence of these structures was linked to significantly better overall survival for patients with advanced melanoma.
A new study found that a gene-based blood test can accurately predict skin cancer recurrence in stage III melanoma patients. The test measures circulating tumor DNA levels to identify those most likely to respond well to therapy.
Researchers found that GSK3β becomes increasingly active in melanoma cells during treatment, helping them survive and adapt despite BRAF inhibitors. Treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth, suggesting blocking this protein could restore sensitivity to treatment.
A small protein involved in neurodegeneration leading to Parkinson's disease also drives a type of skin cancer known as melanoma, according to new research. The study suggests new avenues for drug development to reduce the risk of developing both diseases by targeting alpha-synuclein.
A Rice University-led team developed an implantable 'cytokine factory' that triggers potent immune responses against hard-to-treat cancers. The IL-12 cytokine factory successfully induces the recruitment of tumor-targeting T cells, eliminating local and distal tumors in preclinical models.
A new study found that blocking an enzyme called HPGDS may be a way to improve melanoma treatment for patients who don't respond to immunotherapy. The enzyme promotes tumor growth and metastasis dissemination by blocking T-cell activity, but blocking it boosts the immune response.
A recent study by the CNIO Melanoma Group has discovered a mechanism by which melanomas evade immune system surveillance. The research found that melanoma cells secrete Midkine, a protein that reduces dendritic cell numbers and reprograms their function to promote tumour development.
A new drug therapy combination inhibiting FAK, RAF, and MEK enzymes has shown promise in prolonging survival rates for preclinical mouse models of metastatic melanoma. The study's findings suggest the oral treatment can both treat and prevent brain metastasis.
Researchers investigated skin cancer risk perceptions and sun-protective behaviors in US adults, finding associations between sociodemographic factors and sunburn risks. Higher education levels, Hispanic origin, and income groups were linked to lower sunburn risks, while married or partnered individuals had higher risks.
Researchers at Tufts University have developed a cancer vaccine that amplifies the visibility of tumor antigens to the immune system, leading to potent responses and lasting immunological memory. The vaccine works against multiple solid tumors in animal models, including melanoma, triple-negative breast cancer, and ovarian cancer.
Researchers have developed a 'gut-on-chip' model that replicates intestinal inflammation and predicts response to immunotherapy in melanoma patients. The device differentiates between major intestinal populations and reproduces realistic environments.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
Researchers have discovered a green-produced nanosilver-chlorhexidine complex with enhanced antimicrobial and anti-tumor properties. The complex exhibits 18-fold stronger anti-melanoma activity compared to non-functionalized silver nanoparticles.
Researchers at Mayo Clinic developed patient-derived organoid models to study uveal melanoma, a common type of eye cancer. These 3D models accurately represent the disease's genetic and biological characteristics, enabling better understanding and treatment development.
A new combination therapy combining systemic interferon-I with local imiquimod application showed promising results in treating melanoma and breast cancer. The therapy activated the adaptive immune system to fight distant metastases, reducing tumor relapses and increasing sensitivity to checkpoint inhibitors.
A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.
The study identified a modified imaging approach and volumetric measurements as more accurate in predicting survival compared to other methods. These approaches worked well even for small tumors, suggesting they should be included in future studies.
Researchers developed biodegradable polymeric nanoparticles that selectively target cancer cells with two approved drug pairs for skin and breast cancers. The treatment showed significantly enhanced therapeutic effects, reduced tumor size, and prolonged median survival in mice.
Researchers found that the interaction between TPC2 and Rab7a promotes tumor growth and metastasis in melanoma. The study suggests that targeting this signaling pathway could lead to new therapeutic strategies for skin cancer treatment.
A new study found that a remote telemedicine tool called SpotCheck is highly accurate in diagnosing melanoma, with experts able to remotely examine skin lesions using dermoscopy. The tool has the potential to address diagnostic and treatment disparities for lower-income populations with limited access to dermatologists.
A geospatial analysis found that areas with more tanning bed facilities experience higher rates of melanoma. The study identified six high-risk clusters and seven low-risk clusters, suggesting a significant association between access to tanning beds and increased melanoma incidence.
A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.
This study reveals a substantial increase in US elderly cutaneous malignant melanoma incidence rates, peaking at 1.53 per 1,000 males and 0.59 per 1,000 females aged 85+ from 2012 to 2016. Incidence rates escalated with age and birth cohort, with continuous increases observed.
Researchers found that ApoE protects melanoma cells from ferroptosis by increasing antioxidant capacity and neutralizing lipids. This discovery highlights the APOE gene as a critical factor in melanoma cell survival, potentially opening new avenues for treatment.
Researchers at ChristianaCare Gene Editing Institute use CRISPR tools to safely disable gene mutation linked to treatment-resistant melanoma. The approach targets melanoma tumor cells while leaving healthy cells alone, restoring sensitivity to anticancer drugs.
Researchers have developed a new method to detect melanoma using tumour-specific antibodies, which can accurately identify stage I and II melanoma patients. The study found that these antibodies showed high sensitivity and specificity in detecting melanoma, with an AUC value of up to 0.981.
Dr. Roger Lo has been awarded a $2 million NIH grant to investigate ways to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors. The team aims to target genetic instability and immune evasion to stabilize the melanoma genome and make it more vulnerable to immune attacks.
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
A study analyzing long-term melanoma data reveals that men and women experience different patterns of melanoma development, with women having higher rates in early life but later in life. The research also shows that melanomas arise most commonly on the trunk and head/neck in men, while on limbs in women.
A recent study in Sweden found a significant decline in both melanoma incidence and mortality among individuals aged 30-49. The causes of this downward trend are unclear but may be attributed to increased UV protection, public health campaigns, demographic changes, or advancements in melanoma treatment.
A new study found that skin cancer incidence in young adults declined in Sweden around 2015. The decrease in incidence and mortality is attributed to increased awareness of sun protection, reduced access to sunbeds, and changes in lifestyle habits such as spending more time indoors. The study suggests that continued emphasis on sun pro...
Researchers at Johns Hopkins Medicine found that age-related changes in male fibroblasts contribute to more aggressive and treatment-resistant melanomas. The study discovered that male fibroblasts accumulate reactive oxygen species and produce higher levels of BMP2, leading to increased DNA damage and resistance to targeted therapies.
A Mayo Clinic study found that people with monoclonal B-cell lymphocytosis (MBL) have a 92% elevated risk of developing melanoma. MBL is a precursor to chronic lymphocytic leukemia and also increases the risk of cancers originating in the lymphatic system and serious infections.
A genetic variant in the Syntaxin 17 gene determines the speed of hair greying and susceptibility to skin melanoma in horses. The study found three gene variants at the Grey locus, with the G3 variant associated with a higher risk of melanoma.
Researchers developed a new tool to track immune health patterns over time, revealing how checkpoint inhibitor therapies work together to recruit new T cells. The study found that the combination therapy produces waves of new T cells with each dose, rather than continually strengthening existing ones.
Researchers uncovered how combining immunotherapies targeting PD1 and LAG3 enhances CD8+ T cell responses, leading to improved cancer-killing prowess and enhanced survival rates. The studies also revealed that relatlimab is not inert and can be combined with other immunotherapies to improve responses.
Researchers discuss diverse BRAF alterations found in human cancers and strategies to inhibit them. Class I BRAF inhibitors represent a landmark achievement in precision oncology, with FDA-approved dabrafenib/trametinib for metastatic BRAF p.V600E-mutant solid tumors.
Researchers identified a potential antigen for TCR recognition in melanoma, suggesting that RNLS protein could be recognized by T cells leading to local immune responses against the cancer. The study found that chemical complementarity between melanoma-resident TCR CDR3s and renalase-1 protein correlates with increased melanoma survival.
A Phase 1 study evaluates an individualized neoantigen therapy, showing it is well-tolerated and boosts immune activity against cancer-causing cells. The therapy induces multiple forms of T cell proliferation and sustained responses in patients with melanoma and lung cancer.
Researchers discuss how PROM2 is a predictive biomarker of distant metastases and shorter survival among patients with stage III melanomas. They also demonstrate that runaway metastasis is closely linked to PROM2 overexpression, through increased epithelial-to-mesenchymal transition marker expression and ferroptosis resistance.
A study found that increased expression of human carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) on immune cells is associated with treatment-resistant melanoma. CEACAM1 is now considered a potential therapeutic target for patients with resistant tumors.
Researchers found correlations between MIF and DDT levels with patient survival outcomes in melanoma patients. Higher CD74:MIF and CD74:DDT levels were associated with improved survival and enrichment of inflammatory markers.
A new photodynamic therapy method has been shown to effectively eradicate ocular melanoma in mice, with the technique delivering two photons and minimizing damage to healthy tissue. The approach offers a promising alternative to current treatments that are often ineffective or invasive.
Researchers at the University of Zurich have discovered a factor secreted by tumor cells that impeds the effectiveness of therapies. The POSTN gene plays an important role in resistant tumors and triggers resistance through its interaction with immune cells, particularly macrophages.
A study conducted by Oregon Health & Science University and Lewis & Clark College found that increasing melanoma literacy combined with strengthening skin-check confidence is key to increasing early detection. Social media ads were used to boost knowledge and confidence, leading to improved survival rates when melanoma is caught early.
Researchers identify key factors that determine when melanoma metastasizes, shedding light on optimal treatment strategies. Understanding tumor doubling time and risk assessment can help clinicians select high-risk patients who may benefit from adjuvant systemic therapy.
Researchers discovered a new way to effectively treat melanoma using nutrients to reactivate suppressed metabolic pathways in cancer cells. The innovative treatment, involving tyrosine nanomicelles, showed promising results in mice and lab-derived human cells, inhibiting tumour growth and reducing glycolysis.
Researchers at Francis Crick Institute develop a new genetic therapy that silences mutated NRAS gene in cells with congenital melanocytic naevus syndrome (CMN), potentially reversing debilitating giant moles. The treatment has shown promising results in mice and could be used to reduce cancer risk in affected children and adults.
Researchers have uncovered key tumor-stroma interactions that drive drug resistance in melanoma leptomeningeal disease. The study identifies a potential therapeutic target by inhibiting SERPINA3-mediated signaling.
A Swansea University-led project aims to address the concerning rise of skin cancer in Wales by exploring current perceptions of tanning among children, parents/carers, and educators. The results will support the development of a new sun-safety educational toolkit for the Welsh curriculum.
Researchers at Northwestern University discovered an attenuated virus that can help eliminate cancer in mice and prevent future tumor development. The therapy works by raising 'red flags' on tumors to alert immune cells to attack them.
A new strategy for improving melanoma treatment involves targeting the communication between immune cells within the tumor. By neutralizing specific molecules, researchers found that CD8+ T cell activity against tumors increased while T regulatory cells' ability to inhibit the immune response decreased.
A research team from the University of Liège has discovered that inhibition of VARS enzyme can prevent therapeutic resistance in melanoma by resensitising tumours. This breakthrough offers new hope for patients with resistant melanoma, paving the way for treatment combinations and enhancing targeted therapy efficacy.
The first phase 1 trial of the bispecific antibody FS222 demonstrates promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy. Preliminary results show partial or complete objective response rates in various tumor types.
The NADINA trial found that 59% of patients responded well to neoadjuvant immunotherapy before surgery, allowing them to forgo adjuvant treatment. This treatment approach also showed rapid effects, with 95% of patients remaining tumor-free after just six weeks.
Researchers have identified collagen features as valuable biomarkers for evaluating melanoma immunotherapy response. Single-fiber characteristics were found to be more sensitive to treatment-induced changes than bulk collagen features, offering insights into collagen remodeling over time.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
Researchers found that up to one in seven melanoma patients carry cancer susceptibility genes, suggesting family history may be a bigger risk factor than previously thought. This discovery supports the idea that there are risk factors beyond sun exposure that can influence an individual's chances of developing melanoma.
Researchers have discovered a liquid biopsy biomarker that can identify the effectiveness of treatment at an early stage, enabling more individualized treatment for melanoma patients. The biomarker, SHOX2 methylation in circulating cell-free DNA, was found to be elevated in 60% of melanoma patients and correlated with response to therapy.